A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Trial Profile

A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Glasdegib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Apr 2018 Status changed from recruiting to discontinued.
    • 12 Dec 2017 Results of the single arm lead-in cohort (n=21) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 27 Oct 2017 Planned End Date changed from 24 Dec 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top